Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Champions Oncology, Inc.
Champions Oncology, Inc. News
Champions Oncology, Inc. Quantitative Score
About Champions Oncology, Inc.
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Champions Oncology, Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Champions Oncology, Inc. Financials
Table Compare
Compare CSBR metrics with: | |||
|---|---|---|---|
Earnings & Growth | CSBR | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CSBR | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CSBR | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CSBR | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Champions Oncology, Inc. Income
Champions Oncology, Inc. Balance Sheet
Champions Oncology, Inc. Cash Flow
Champions Oncology, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Champions Oncology, Inc. Executives
| Name | Role |
|---|---|
| Dr. Ronnie Morris M.D. | Chief Executive Officer & Director |
| Mr. David Barry Miller M.B.A. | Chief Financial Officer |
| Dr. Maria Mancini Ph.D. | Chief Operating Officer |
| Ms. Rachel A. Bunting M.B.A., M.S., MBA, MS | Vice President of Global Marketing |
| Dr. Marianna Zipeto Ph.D. | Executive Vice President of Commercial, Research Services & Partnering |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Dr. Ronnie Morris M.D. | Chief Executive Officer & Director | 1966 | 400K | |
| Mr. David Barry Miller M.B.A. | Chief Financial Officer | Male | 1969 | 260K |
| Dr. Maria Mancini Ph.D. | Chief Operating Officer | -- | ||
| Ms. Rachel A. Bunting M.B.A., M.S., MBA, MS | Vice President of Global Marketing | Female | -- | |
| Dr. Marianna Zipeto Ph.D. | Executive Vice President of Commercial, Research Services & Partnering | -- |
Champions Oncology, Inc. Insider Trades
| Date | 25 Mar |
| Name | Breitfeld Philip P. |
| Role | Director |
| Transaction | Disposed |
| Type | J-Other |
| Shares | 4150 |
| Date | 12 Nov |
| Name | Breitfeld Philip P. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 18715 |
| Date | 12 Nov |
| Name | SIDRANSKY DAVID |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 21880 |
| Date | 12 Nov |
| Name | Mendelson Daniel Newman |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 21590 |
| Date | 12 Nov |
| Name | TOBIN SCOTT R |
| Role | Director, 10 percent owner |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 34550 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 25 Mar | Breitfeld Philip P. | Director | Disposed | J-Other | 4150 |
| 12 Nov | Breitfeld Philip P. | Director | Acquired | A-Award | 18715 |
| 12 Nov | SIDRANSKY DAVID | Director | Acquired | A-Award | 21880 |
| 12 Nov | Mendelson Daniel Newman | Director | Acquired | A-Award | 21590 |
| 12 Nov | TOBIN SCOTT R | Director, 10 percent owner | Acquired | A-Award | 34550 |